鼻アレルギーに対するリザベンの臨床試験成績

減量・中止について

抄録

Tranilast, inhibitor of mediator release, was administered to 163 cases of whole year nasal allergy for more than 8 weeks to examine its effectiveness and safety. From the 8th week on, dose reduction and withdrawal of Tranilast were under taken. Observations of exacerbation and/or relapse then continued for 13 weeks to find the optimum dose reduction and withdrawal procedures. On the basis of “Patients' impressions” 8 weeks after administration, dose reduction and withdrawal were set up. A part of “Very well”, administration was withdrawn. The other part of “Very well”, was reduced 3 to 1 capsule.“Well” or “Slightly well”, was reduced 3 to 2 capsules. Withdraw or reduce 3 to 1 capsule was determined randomly. The results of the overall estimation revealed a rate of effectiveness of 62.2 and 90.0% after 4 and 8 weeks, respectively. A rate of relapse following dose reduction and withdrawal was 25.0-33.3% without a difference in the rate of relapse according to dose reduction procedures. This suggests the necessary selection of a dose reduction procedure according to the degree of effectiveness of Tranilast.